A Study Explore WJ01075 Tablets in Patients With Advanced Solid Tumors

Phase 1

Terminated

• Conditions: Advanced Solid Tumors
• Interventions: Drug: WJ01075

• Registration Number: NCT05470933
• Lead Sponsor: Suzhou Junjing BioSciences Co., Ltd.

Brief Summary

This is a phase I study to Investigate the safety and tolerability, DLT(Dose limited toxicity), MTD(Maximum tolerated dose), and RP2D(Recommended phase II dose) of WJ01075 tablets in patients with advanced malignant solid tumors, including phase Ia (dose escalation phase) and Phase Ib (dose expansion phase,cohort expansion phase).The study includes screening, treatment and follow-up periods.

In phase Ia, accelerated titration (the first two dose groups) and "3 + 3" combination (the subsequent dose group) were used for dose escalation.

In phase Ib, specific dose groups will be selected for dose expansion according to PK(Pharmacokinetics) and safety data of different dose groups in dose escalation phase.It is planned that SMC(Safety Monitoring Committee) will select one or more dose groups based on previous data for cohort expansion studies to further determine RP2D, safety tolerability and initial efficacy.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-07-07
• Study First Submitted QC: 2022-07-20
• Study First Posted: 2022-07-22
• Study Start: 2022-08-23
• Primary Completion: 2023-04-18
• Study Completion: 2023-04-18
• Status Verified: 2023-08
• Last Update Submitted: 2023-08-29
• Last Update Posted: 2023-09-01

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 7

Inclusion Criteria

1. Patient with advanced malignant solid tumors clearly diagnosed pathologically and/or cytologically, who have failed to receive standard treatment, or who currently do not/or refuse standard treatment, or who are intolerant to standard treatment;

2. Patient must have at least one measurable lesion as defined per RECIST v1.1;

3. Aged between 18 and 75 (including 18 and 75), male and female patients;

4. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score ≤1;

5. Life expectancy ≥ 3 months;

6. The functions of patients' major organs were basically normal, and the laboratory tests performed within 7 days prior to the first administration of study drugmet the following criteria, Patients must not have required a blood transfusion or growth factor support within 14 days before the examination:

   Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤2.5 × Upper limit of Normal (ULN); Total Bilirubin≤ 1.5×ULN; International Normalized Ratio (INR) ≤1.5; Creatinine ≤ 1.5 × ULN, and Creatinine Clearance Rate (calculated by Cockcroft-Gault formula) ≥ 50 mL/min; Hemoglobin (Hg) ≥ 90g/L; Platelets ≥ 100×10⋀9/L; Absolute Neutrophil Count(ANC) ≥ 1.5×10⋀9/L

7. Fertile women must confirm a negative blood pregnancy test within 7 days prior to the first administration of study drug;All enrolled patients (both male and female) are required to use adequate and effective contraceptive measures throughout the treatment period and within 3 months after the end of treatment;

8. Those who voluntarily participate in the study and sign the written Informed Consent Form upon full informed consent.

Exclusion Criteria

1. Prior treatment with XPO1 inhibitors;
2. Have a history of allergy to any component or excipient of WJ010175 tablets;
3. Patient with a primary malignancy other than the tumor treated in the study within 5 years prior to the first administration of study drug (exceptions include cured malignancies that did not recur within 3 years prior to enrollment;Basal cell and squamous cell carcinoma completely resected;Complete excision of any type of carcinoma in situ, etc.);
4. Received other anti-tumor therapies, including but not limited to chemotherapy, radiotherapy, targeted therapy, immunotherapy and other anti-tumor therapies (such as anti-tumor traditional Chinese medicine), within 4 weeks or 5 half-life periods (whichever is longer) prior to the first administration of study drug;Or long-term treatment with potent CYP1A2 inhibitors, potent CYP3A4 inducers and potent CYP3A4 inhibition;
5. Thrombosis or embolism occurred within 6 months prior to the first administration of study drug;
6. Received medium or major surgical treatment within 4 weeks prior to the first administration of study drug, other than diagnostic biopsy ;
7. Any of the following conditions within 6 months prior to the first administration of study drug: New York Cardiology Association (NYHA) > Grade II cardiac insufficiency, congestive heart failure, severe/unstable angina pectoris (symptoms of resting angina pectoris), myocardial infarction, arrhythmias requiring treatment, uncontrolled hypertension or hypertensive crisis or hypertensive encephalopathy;
8. Adverse events and/or complications caused by previous treatment are not relieved to < Level 2 (per NCI-CTCAE V5.0);Any level of hair loss/pigmentation and long-term toxicity caused by other treatment, other than those that the investigator diagnosiss cannot be recovered and do not affect study administration or compliance and patient safety;
9. Patient with central nervous system metastasis or tumors originating in the central nervous system;,
10. Patient with grade ≥ 2 neuropathy (per NCI-CTCAE V5.0);
11. Severe infections requiring antibiotic treatment within 14 days prior to the first administration of study drug ( > CTCAE Grade 2 ), such as severe pneumonia, bacteremia, infection complications requiring hospitalization;
12. Uncontrolled pericardial effusion, pleural effusion or clinically obvious moderate to severe abdominal effusion during screening is defined as meeting the following criteria: having clinical symptoms and detectable thoracic and abdominal effusion during physical examination;Or in the screening process, the thoracoabdominal effusion needs to be punctured pumping liquid and/or intravenously administered;
13. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
14. Patient has serious psychological or mental abnormalities affecting the compliance of the subjects to participate in the study;
15. With active Hepatitis B, or Hepatitis C, or Human Immunodeficiency Virus positive [HIV (+)] and syphilis antibody (+);Note: Hepatitis B virus surface Antigen (HBsAg) or core antibody (HBcAb) positive should be tested for HBV-DNA, and HBV-DNA should be below the lower limit of the reference range.Patients who are positive for Hepatitis C virus Antibody (HCV Ab) will be tested for HCV RNA and can be enrolled if they are below the upper limit of normal.
16. With Gastrointestinal dysfunction that may affect drug absorption (e.g., intestinal obstruction, inability to swallow tablets, malabsorption syndrome, uncontrollable nausea or vomiting, etc.);
17. Pregnant or lactating women or men who still have reproductive needs;
18. Other conditions that the investigator considers to be ineligible for inclusion, including but not limited to subjects whose body weight is less than ideal and who are expected to be significantly affected by weight change as determined by the investigator.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
WJ01075 tablets	WJ01075	Once a week (QW).

Primary Outcome Measures

Name	Time	Method
Maximum tolerated dose (MTD)	2 years	Maximum tolerated dose (MTD)
Dose limited toxicity (DLT)	3 years	incidence and severity of Dose limited toxicity(DLT);
Adverse event (AE)	3 years	incidence and severity of adverse event (AE), Abnormal changes in laboratory and other tests of clinical significance;
Recommended phase II dose (RP2D)	2 years	Recommended phase II dose (RP2D)
Serious adverse event (SAE)	3 years	incidence and severity of Serious adverse event (SAE);

Secondary Outcome Measures

Name	Time	Method
Objective response rate(ORR)	2 years	Efficacy endpoints: Objective response rate(ORR) per RECIST v1.1
Time to response(TTR)	2 years	Efficacy endpoints: Time to response(TTR) per RECIST v1.1
Overall survival (OS)	2 years	Efficacy endpoints: Overall survival (OS) per RECIST v1.1
Clearance rate (CL/F)	2 years	Pharmacokinetic (PK) parameter : Clearance rate (CL/F) after a single dose;
Elimination half-life time ( t1/2) and other parameters	2 years	Pharmacokinetic (PK) parameter : Elimination half-life time ( t1/2) and other parameters after a single dose;
Steady state peak concentration(Cssmax)	2 years	Pharmacokinetic (PK) parameter : Steady state peak concentration(Cssmax) after repeated administration;
Fluctuation coefficient (DF)	2 years	Pharmacokinetic (PK) parameter : Fluctuation coefficient (DF) after repeated administration;
Duration of response (DOR)	2 years	Efficacy endpoints: Duration of response (DOR) per RECIST v1.1
Progression-free survival (PFS)	2 years	Efficacy endpoints: Progression-free survival (PFS) per RECIST v1.1
Maximum plasma concentration (Cmax)	2 years	Pharmacokinetic (PK) parameter : Maximum plasma concentration (Cmax) after a single dose;
Disease control rate (DCR)	2 years	Efficacy endpoints: Disease control rate (DCR) per RECIST v1.1
Peak time(Tmax)	2 years	Pharmacokinetic (PK) parameter : Peak time(Tmax) after a single dose;
Apparent volume of distribution (Vd/F)	2 years	Pharmacokinetic (PK) parameter : Apparent volume of distribution (Vd/F) after a single dose;
Elimination rate constant (λz)	2 years	Pharmacokinetic (PK) parameter : Elimination rate constant (λz) after a single dose;
Steady state valley concentration(Cssmin)	2 years	Pharmacokinetic (PK) parameter : Steady state valley concentration(Cssmin) after repeated administration;
Steady state Area under blood concentration - time curve(AUCss)	2 years	Pharmacokinetic (PK) parameter : Steady state Area under blood concentration - time curve(AUCss) after repeated administration;
Area under blood concentration - time curve (AUC)	2 years	Pharmacokinetic (PK) parameter : Area under blood concentration - time curve (AUC) after a single dose;
Steady-state distribution volume(Vss )	2 years	Pharmacokinetic (PK) parameter : Steady-state distribution volume(Vss ) after repeated administration;
Average steady-state plasma concentration(Css-av)	2 years	Pharmacokinetic (PK) parameter : Average steady-state plasma concentration(Css-av) after repeated administration;
Elimination half-life time ( t1/2)	2 years	Pharmacokinetic (PK) parameter : Elimination half-life time ( t1/2) after repeated administration;
Accumulation coefficient (AR) and other parameters	2 years	Pharmacokinetic (PK) parameter : Accumulation coefficient (AR) and other parameters after repeated administration;

Trial Locations

Locations (1)

Harbin Medical University Cancer Hospital; 🇨🇳 Harbin, Heilongjiang, China